Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)
BHVN.N on New York Stock Exchange
27.10USD
25 Apr 2018
27.10USD
25 Apr 2018
Change (% chg)
$0.67 (+2.54%)
$0.67 (+2.54%)
Prev Close
$26.43
$26.43
Open
$26.37
$26.37
Day's High
$27.36
$27.36
Day's Low
$25.60
$25.60
Volume
54,418
54,418
Avg. Vol
138,393
138,393
52-wk High
$39.20
$39.20
52-wk Low
$16.51
$16.51
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 0.00 | -0.751 |
| Sep '17 | 0.00 | -1.194 | |
| Jun '17 | 0.00 | -1.784 | |
| Mar '17 | 0.00 | -1.738 | |
| FY 2016 | Dec '16 | 0.00 | -0.499 |
| Sep '16 | 0.00 | -2.119 | |
| Jun '16 | 0.00 | -0.546 | |
| Mar '16 | 0.00 | -0.121 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 3 | 0.00 | 0.00 | 0.00 | -- |
| Quarter Ending Sep-18 | 3 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-18 | 6 | 0.17 | 1.04 | 0.00 | -- |
| Year Ending Dec-19 | 6 | 3.35 | 8.54 | 0.00 | -- |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 6 | -1.24 | -0.83 | -2.38 | -- |
| Quarter Ending Sep-18 | 6 | -1.10 | -0.85 | -1.44 | -- |
| Year Ending Dec-18 | 6 | -4.52 | -3.46 | -5.17 | -- |
| Year Ending Dec-19 | 6 | -4.23 | -2.95 | -5.58 | -- |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
Dividends
Growth Rates
Financial Strength
Profitability Ratios
Efficiency
Management Effectiveness
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | -91.00 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Biohaven Pharmaceutical Holding Company Ltd
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Biohaven Announces Robust Clinical Data With Single Dose Rimegepant That Defines Acute And Durable Benefits To Patients
- Biohaven plunges as investors pit migraine data against Allergan's drug
- Biohaven tumbles as migraine drug efficacy fails to impress investors
- BRIEF-Biohaven Says Achieved Both Co-Primary Regulatory Endpoints In Two Pivotal Phase 3 Trials Of Rimegepant
- BRIEF-Biohaven restructures license agreement with Bristol-Myers Squibb to reduce royalties payable on its migraine product candidates
Institutional Holders
| % Shares Owned: | 54.11% |
| # of Holders: | 127 |
| Total Shares Held: | 20,891,208 |
| 3 Mo. Net Change: | 33,592 |
| # New Positions: | 4 |
| # Closed Positions: | 3 |
| # Increased Positions: | 9 |
| # Reduced Positions: | 7 |
| # Net Buyers: | 2 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.